Dose escalation of a curcuminoid formulation

被引：1032

作者：

Christopher D Lao

Mack T Ruffin

Daniel Normolle

Dennis D Heath

Sandra I Murray

Joanne M Bailey

Martha E Boggs

James Crowell

Cheryl L Rock

Dean E Brenner

机构：

[1] Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0930

[2] Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109-0708

[3] Department of Biostatistics Core, Cancer Center, University of Michigan, Ann Arbor, MI 48109-0473

[4] Cancer Prevention and Control Program, University of California San Diego, La Jolla, CA 92093-0901

[5] Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892

[6] Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA 92093-0901

来源：

BMC Complementary and Alternative Medicine | / 6卷 / 1期

关键词：

Curcumin; Minimal Toxicity; Poor Bioavailability; Common Toxicity Criterion Version; Single Dose Oral Administration;

D O I：

10.1186/1472-6882-6-10

中图分类号：

学科分类号：

摘要：

Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed. Methods: A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3 Complex™ Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 Mg. Results: Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg. Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent. © 2006 Lao et al; licensee BioMed Central Ltd.

引用

页数：4

共 23 条

[1]

Mukhopadhyay A., Basu N., Ghatak N., Gujral P.K., Anti-inflammatory and irritant activities of curcumin analogues in rats, Agents Actions, 12, 4, pp. 508-515, (1982)

[2]

Srimal R.C., Dhawan B.N., Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent, J Pharm Pharmacol, 25, 6, pp. 447-452, (1973)

[3]

Rao C.V., Rivenson A., Simi B., Reddy B.S., Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound, Cancer Res, 55, 2, pp. 259-266, (1995)

[4]

Huang M.T., Smart R.C., Wong C.Q., Conney A.H., Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate, Cancer Res, 48, 21, pp. 5941-5946, (1988)

[5]

Huang M.T., Lou Y.R., Ma W., Newmark H.L., Reuhl K.R., Conney A.H., Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice, Cancer Res, 54, 22, pp. 5841-5847, (1994)

[6]

Aggarwal B.B., Kumar A., Bharti A.C., Anticancer potential of curcumin: Preclinical and clinical studies, Anticancer Res, 23, 1 A, pp. 363-398, (2003)

[7]

Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions, Anticancer Res, 21, 4 B, pp. 2895-2900, (2001)

[8]

Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., Pirmohamed M., Marnett L.J., Gescher A.J., Steward W.P., Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer, Clin Cancer Res, 7, 7, pp. 1894-1900, (2001)

[9]

Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S., Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers, Planta Med, 64, 4, pp. 353-356, (1998)

[10]

Heath D.D., Pruitt M.A., Brenner D.E., Rock C.L., Curcumin in plasma and urine: Quantitation by high-performance liquid chromatography, J Chromatogr B Analyt Technol Biomed Life Sci, 783, 1, pp. 287-295, (2003)

← 1 2 3 →